Literature DB >> 22378497

Transcriptional profile of native CD271+ multipotential stromal cells: evidence for multiple fates, with prominent osteogenic and Wnt pathway signaling activity.

Sarah M Churchman1, Frederique Ponchel, Sally A Boxall, Richard Cuthbert, Dimitrios Kouroupis, Tarek Roshdy, Peter V Giannoudis, Paul Emery, Dennis McGonagle, Elena A Jones.   

Abstract

OBJECTIVE: Controversy surrounds the identity and functionality of rare bone marrow-derived multipotential stromal cells (BM-MSCs), including their differentiation capabilities, their relationship to pericytes and hematopoiesis-supporting stromal cells, and the relevance of their culture-expanded progeny in studies of skeletal biology and development of cell-based therapies. The aim of this study was to clarify the nature of candidate BM-MSCs by profiling transcripts that reflect different aspects of their putative functions in vivo.
METHODS: Rare, sorted BM-derived CD45(-/low) CD271(bright) (CD271) cells were analyzed using 96-gene expression arrays focused on transcripts relevant to mesenchymal-lineage differentiation (toward bone, cartilage, fat, or muscle), hematopoietic and stromal support, and molecules critical to skeletal homeostasis. These cells were compared to matched CD45+ CD271- hematopoietic-lineage cells, culture-expanded MSCs, and skin fibroblasts. When feasible, transcription was validated using flow cytometry.
RESULTS: CD271 cells had a transcriptional profile consistent with the multiple fates of in vivo MSCs, evident from the observed simultaneous expression of osteogenic, adipogenic, pericytic, and hematopoiesis-supporting genes (e.g., SP7 [osterix], FABP4 [fatty acid binding protein 4], ANGPT1 [angiopoietin 1], and CXCL12 [stromal cell-derived factor 1], respectively). Compared to culture-expanded MSCs and fibroblasts, CD271 cells exhibited greater transcriptional activity, particularly with respect to Wnt-related genes (>1,000-fold increased expression of FRZB [secreted frizzled-related protein 3] and WIF1 [Wnt inhibitory factor 1]). A number of transcripts were identified as novel markers of MSCs.
CONCLUSION: The native, BM-derived in vivo MSC population is endowed with a gene signature that is compatible with multiple functions, reflecting the topographic bone niche of these cells, and their signature is significantly different from that of culture-expanded MSCs. This indicates that studies of the biologic functions of MSCs in musculoskeletal diseases, including osteoporosis and osteoarthritis, should focus on in vivo MSCs, rather than their culture-adapted progeny.
Copyright © 2012 by the American College of Rheumatology.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22378497     DOI: 10.1002/art.34434

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  66 in total

Review 1.  The aging hematopoietic stem cell niche: Phenotypic and functional changes and mechanisms that contribute to hematopoietic aging.

Authors:  Sarah E Latchney; Laura M Calvi
Journal:  Semin Hematol       Date:  2016-10-19       Impact factor: 3.851

2.  Identification and isolation of small CD44-negative mesenchymal stem/progenitor cells from human bone marrow using elutriation and polychromatic flow cytometry.

Authors:  Sean R R Hall; Yajuan Jiang; Elizabeth Leary; Greg Yavanian; Sarah Eminli; David W O'Neill; Wayne A Marasco
Journal:  Stem Cells Transl Med       Date:  2013-07-11       Impact factor: 6.940

3.  Mesenchymal Stem/Stromal Cells in Regenerative Medicine: Can Preconditioning Strategies Improve Therapeutic Efficacy?

Authors:  Richard Schäfer; Gabriele Spohn; Patrick C Baer
Journal:  Transfus Med Hemother       Date:  2016-07-20       Impact factor: 3.747

Review 4.  Cell-based therapies for cardiac disease: a cellular therapist's perspective.

Authors:  Pampee P Young; Richard Schäfer
Journal:  Transfusion       Date:  2014-08-22       Impact factor: 3.157

Review 5.  [Mesenchymal stem/stroma cells : Therapeutic potential in the treatment of autoimmune diseases].

Authors:  R Schäfer; T Daikeler
Journal:  Z Rheumatol       Date:  2016-10       Impact factor: 1.372

Review 6.  Mesenchymal stem cell subpopulations: phenotype, property and therapeutic potential.

Authors:  Miaohua Mo; Shan Wang; Ying Zhou; Hong Li; Yaojiong Wu
Journal:  Cell Mol Life Sci       Date:  2016-05-03       Impact factor: 9.261

Review 7.  Bone repair with skeletal stem cells: rationale, progress to date and clinical application.

Authors:  Elena A Jones; Peter V Giannoudis; Dimitrios Kouroupis
Journal:  Ther Adv Musculoskelet Dis       Date:  2016-04-01       Impact factor: 5.346

8.  Multipotential stromal cell abundance in cellular bone allograft: comparison with fresh age-matched iliac crest bone and bone marrow aspirate.

Authors:  Thomas G Baboolal; Sally A Boxall; Yasser M El-Sherbiny; Timothy A Moseley; Richard J Cuthbert; Peter V Giannoudis; Dennis McGonagle; Elena Jones
Journal:  Regen Med       Date:  2014-03-12       Impact factor: 3.806

9.  SOST, an LNGFR target, inhibits the osteogenic differentiation of rat ectomesenchymal stem cells.

Authors:  Gang Li; Junyu Liu; Manzhu Zhao; Yingying Wang; Kun Yang; Chang Liu; Yong Xiao; Xiujie Wen; Luchuan Liu
Journal:  Cell Prolif       Date:  2017-12-10       Impact factor: 6.831

10.  Priming 3D cultures of human mesenchymal stromal cells toward cartilage formation via developmental pathways.

Authors:  Matteo Centola; Beatrice Tonnarelli; Stefan Schären; Nicolas Glaser; Andrea Barbero; Ivan Martin
Journal:  Stem Cells Dev       Date:  2013-07-27       Impact factor: 3.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.